Oslo, Norway, 15 August 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will announce its second quarter and first half year 2018 results on Thursday, 23 August 2018. A presentation by Targovax's management to... read more

DUBLIN, Ireland and TREVOSE, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it intends to offer and sell 9,000,000 of its ordinary shares in an underwritten public offering. The Company also intends to grant the underwri... read more

Fri, Aug 10, 2018 14:00 CETMIPS releases its Interim report for the period January to June on August 16 at 7:30 am (CET). Johan Thiel, President and CEO and Max Strandwitz CFO, will present the results the same day at 10:00 am CET, at a conference call. The conference call will be held in... read more

Company announcement, Helsinki, 9 August 2018 at 9:00 AM Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), the targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, will... read more

Stockholm – August 9, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Anders Martin-Löf, has been appointed as the new CFO of Oncopeptides and will join the company in November. CFO Birgitta Ståhl has decided to step down as the CFO as the Company expands the orga... read more